Existing Intellectual Property. Except as the parties may otherwise expressly agree in writing, each party shall continue to own its existing patents, trademarks, copyrights, trade secrets and other intellectual property, without conferring any interests therein on the other party. Without limiting the generality of the preceding sentence, CLIENT shall retain all right, title and interest arising under the United States Patent Act, the United States Trademark Act, the United States Copyright Act and all other applicable laws, rules and regulations in and to all Drug Products, Bulk Drug Substance, Labeling and trademarks associated therewith (collectively, “CLIENT’s Intellectual Property”). Neither A▇▇▇▇▇ nor any third party shall acquire any right, title or interest in CLIENT’s Intellectual Property by virtue of this Agreement or otherwise, except to the extent expressly provided herein.
Appears in 3 contracts
Sources: Drug Product Development and Clinical Supply Agreement (Bio-Path Holdings Inc), Company Plasmid Dna Production Agreement (Biocancell Therapeutics Inc.), Company Plasmid Dna Production Agreement (Biocancell Therapeutics Inc.)
Existing Intellectual Property. Except as the parties Parties may otherwise expressly agree in writing, each party Party shall continue to own its existing patents, trademarks, copyrights, trade secrets and other intellectual property, without conferring any interests therein on the other partyParty. Without limiting the generality of the preceding sentence, CLIENT Client shall retain all right, title and interest arising under the United States Patent Act, the United States Trademark Act, the United States Copyright Act and all other applicable laws, rules and regulations in and to all Drug Products, Bulk Drug SubstanceBDS, Labeling labeling and trademarks associated therewith (collectively, “CLIENTClient’s Intellectual Property”). Neither A▇▇▇▇▇▇ nor any third party shall acquire any right, title or interest in CLIENTClient’s Intellectual Property Property, express or implied, by virtue of this Agreement or otherwise, except to the extent expressly provided herein.
Appears in 2 contracts
Sources: Product Development and Clinical Supply Agreement, Product Development and Clinical Supply Agreement (Genocea Biosciences, Inc.)
Existing Intellectual Property. Except as the parties may otherwise expressly agree in writing, each party shall continue to own its existing patents, trademarks, copyrights, trade secrets and other intellectual property, without conferring any interests therein on the other party. Without limiting the generality of the preceding sentence, CLIENT AMYLIN shall retain all right, title and interest arising under the United States Patent Act, the United States Trademark Act, the United States Copyright Act and all other applicable foreign and domestic laws, rules and regulations in and to all Drug ProductsProduct, Bulk Pramlintide Drug Substance, Labeling and trademarks associated therewith (collectively, “CLIENTAMYLIN’s Intellectual Property”). Neither A▇▇▇▇▇ BAXTER nor any third party shall acquire any right, title or interest in CLIENTAMYLIN’s Intellectual Property by virtue of this Agreement or otherwise, except to the extent expressly provided herein.
Appears in 1 contract
Sources: Commercial Supply Agreement (Amylin Pharmaceuticals Inc)
Existing Intellectual Property. Except as the parties may otherwise expressly agree in writing, each party shall continue to own its existing patents, trademarks, copyrights, trade secrets and other intellectual propertyIntellectual Property, without conferring any interests therein on the other party. Without limiting the generality of the preceding sentence, CLIENT Client shall retain all right, title and interest arising under the United States Patent Act, the United States Trademark Act, the United States Copyright Act and all other applicable laws, rules and regulations in and to all Drug ProductsClient Product, Bulk Drug SubstanceClient-Supplied Components, Labeling and trademarks associated therewith (collectively, “CLIENT’s Intellectual Property”)therewith. Neither A▇▇▇▇▇▇ nor any third party shall acquire any right, title or interest in CLIENT’s such Intellectual Property by virtue of this Agreement or otherwise, except to the extent expressly provided herein.
Appears in 1 contract
Sources: Clinical and Commercial Services Agreement (Ophthotech Corp.)
Existing Intellectual Property. Except as the parties may otherwise expressly agree in writing, each party shall continue to own its existing patents, trademarks, copyrights, trade secrets and other intellectual property, without conferring any interests therein on the other party. Without limiting the generality of the preceding sentence, CLIENT shall retain all right, title and interest arising under the United States Patent Act, the United States Trademark Act, the United States Copyright Act and all other applicable laws, rules and regulations in and to all Drug Products, Bulk Drug Substance, Labeling and trademarks associated therewith (collectively, “CLIENT’s Intellectual Property”). Neither A▇▇▇▇▇▇ nor any third party shall acquire any right, title or interest in CLIENT’s Intellectual Property by virtue of this Agreement or otherwise, except to the extent expressly provided herein.
Appears in 1 contract
Sources: Drug Product Development and Clinical Supply Agreement
Existing Intellectual Property. Except as the parties may otherwise expressly agree in writingSubject to Section 17.6, each party shall continue to own its existing patents, trademarks, copyrights, trade secrets and other intellectual property, without conferring any interests therein on the other party. Without limiting the generality of the preceding sentence, CLIENT AMYLIN shall retain all right, title and interest arising under the United States Patent Act, the United States Trademark Act, the United States Copyright Act and all other applicable foreign and domestic laws, rules and regulations in and to all Drug Products, Bulk Exenatide Drug Substance, Labeling and trademarks associated therewith (collectively, “CLIENTAMYLIN’s Intellectual Property”). Neither A▇▇▇▇▇ BAXTER nor any third party shall acquire any right, title or interest in CLIENTAMYLIN’s Intellectual Property by virtue of this Agreement or otherwise, except to the extent expressly provided herein.
Appears in 1 contract
Sources: Commercial Supply Agreement (Amylin Pharmaceuticals Inc)